Sugi Predict

Sugi Predict / Compounds / SCHEMBL6524799

SCHEMBL6524799

SCHEMBL6524799

CC(C)(C)OC(=O)Nc1cc(Cl)cc(Br)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ AAK1 Q2M2I8 3/20 0.39
▸ CYP17A1 P05093 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ KCNQ4 P56696 1/20 0.36
▸ KCNQ5 Q9NR82 1/20 0.36
▸ ATR Q13535 1/20 0.36
▸ EPAS1 Q99814 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ P2RX3 P56373 2/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15685473 0.86 GAA (0.37) AAK1CYP17A1EPAS1CA12CA1
SCHEMBL30313207 0.84 HSP90AA1 (0.44) HSP90AA1HSP90AB1CYP17A1RXFP1KCNQ4
SCHEMBL6524156 0.84 LCK (0.40) AAK1CYP17A1RXFP1KCNQ4KCNQ5
SCHEMBL31748884 0.81 RAB9A (0.43) MEN1NPC1HTTRAB9AKMT2A
SCHEMBL13776174 0.80 ATR (0.44) AAK1CYP17A1ATREPAS1CA12
SCHEMBL4601158 0.80 AAK1 (0.44) HSP90AA1HSP90AB1AAK1CYP17A1RXFP1
SCHEMBL15426724 0.80 EGLN2 (0.39) AAK1CYP17A1RXFP1KCNQ4KCNQ5
SCHEMBL31568826 0.79 HSP90AA1 (0.45) HSP90AA1HSP90AB1ATRMEN1RAB9A
SCHEMBL1010291 0.79 HSP90AA1 (0.45) HSP90AA1HSP90AB1ATRMEN1RAB9A
SCHEMBL1007327 0.79 MAPT (0.49) HSP90AA1HSP90AB1ATRMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 — — US claimed
US-8501758-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2013-08-06 — — US claimed
CN-102725283-A Compounds and compositions as protein kinase inhibitors IRM LLC 2012-10-10 — — CN claimed
EP-2470526-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2012-07-04 — — EP claimed
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-15 — — US claimed
WO-2011025927-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — WO claimed
US-20250241915-A1 COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS PFIZER INC. (US) 2025-07-31 — — US disclosed
US-12303509-B2 Compounds for the treatment of BRAF-associated diseases and disorders PFIZER INC. (US) 2025-05-20 — — US disclosed
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 — — US disclosed
US-RE49556-E1 Compounds and compositions as protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-06-20 — — US disclosed
CN-116096710-A 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders 阿雷生物药品公司 2023-05-09 — — CN disclosed
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors ARRAY BIOPHARMA INC (US) 2023-04-13 — — US disclosed
EP-4161907-A1 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS Array BioPharma Inc. (US) 2023-04-12 — — EP disclosed
US-8242260-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS AG (CH) 2012-08-14 — — US disclosed
CN-102596937-A Compounds and compositions as protein kinase inhibitors NOVARTIS AG 2012-07-18 — — CN disclosed
EP-2470526-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2012-07-04 — — EP disclosed
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-15 — — US disclosed
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-15 — — US disclosed
WO-2011025927-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — WO disclosed
US-20110052578-A1 Compounds and Compositions as Protein Kinase Inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241915-A1 COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS BRAF, NRAS, RAF1 HSP90AA1 1106/4885HSP90AB1 852/4885AAK1 1323/4885
US-20110306625-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF HSP90AA1 658/4885HSP90AB1 517/4885AAK1 271/4885
US-20110052578-A1 Compounds and Compositions as Protein Kinase Inhibitors RAF1, BRAF, ARAF HSP90AA1 1904/4885HSP90AB1 1080/4885AAK1 276/4885
US-12303509-B2 Compounds for the treatment of BRAF-associated diseases and disorders BRAF, NRAS, RAF1 HSP90AA1 1106/4885HSP90AB1 852/4885AAK1 1323/4885
US-20230116233-A1 Compounds And Compositions As Protein Kinase Inhibitors BRAF, RAF1, ARAF HSP90AA1 658/4885HSP90AB1 517/4885AAK1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.